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The mammalian liver contains steroid sensitive
processes e.g. the production of alpha-2-globulin in
the mouse (Roy et al., 1974) or the production of
sex hormone binding globulin in the human
(Anderson, 1974), but it is only recently that steroid
hormone receptors have been identified in liver
parenchyma. Oestrogen (Aten et al., 1978; Porter et
al., 1983a), androgen (Levinson & Decker, 1985;
Bannister et al., 1985a) and glucocorticoid receptors
(Bojar et al., 1980) have been identified in both
human and rodent liver. This recent finding of
steroid hormone receptors has prompted research
into their potential role in known hormone related
liver disease; both oestrogen (ER) and androgen
(AR) receptors have been implicated in hepatic
tumour production (Farrell et al., 1973; Hernandez-
Nieto et al., 1977; Francavilla et al., 1984) and are
thought to be intimately involved in the regenera-
tion of rat liver following trauma (Fisher et al.,
1984).
The present study investigated the effect of
diethylnitrosamine (DEN) administration, a known
hepatic carcinogen, on the AR concentration of
male and female rat liver. Although this is a well
established model of hepatic carcinogenesis,
producing tumours in both female and male
animals, no measurements of steroid hormone
receptor levels have been reported until now.
The rats used in the experiments were Wistar
strain bred in the University of Sheffield Zoology
Department. All rats were 9 weeks old at the start
of the experiment.
DEN was incorporated in drinking water
(5mg 100ml-1) and offered ad libitum for up to 16
weeks. Groups were sacrificed after 8 or 16 weeks
of DEN treatment. Control rats were given normal
drinking water, All rats were allowed free access to
a standard laboratory diet.
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Tritium labelled and unlabelled mibolerone (7-
alpha, 17-alpha dimethyl [17 aplha methyl 3H] 19-
nortestosterone; 87Cimmol-1), were obtained from
Amersham International plc, Bucks. Hydroxylapatite
was obtained from BioRad, Richmond, CA, USA.
All other chemicals were of analytical grade and
were obtained from BDH Laboratories, Poole,
Dorset.
Buffers consisted of (i) Tris (10mmol -1),
EDTA (lmmoll-1), Na2MoO4 (10mmoll-1) and
dithiothreitol (1mmoll-1) (TEDGM buffer).
Dithiothreitol was stored as a 0.5mol 1- solution
and added just prior to use; and (ii) Tris
(10mmolI-1) and EDTA (1 mmolI 1) (TE buffer).
Rats were sacrificed by cervical dislocation. The
liver was rapidly removed and chilled. Portions
were either used immediately or snap frozen and
stored at -70°C until analysis.
All procedures were performed at 0-4°C. Tissue
was finely cut, suspended in TEDGM buffer, 1:8
(w/v) and homogenized on a Ystral homogenizer.
Phase contrast microscopy after the final homo-
genization showed intact nuclei but disruption of
the cytosolic envelope. The homogenate was centri-
fuged at 800g for 20min. The supernatant was
further centrifuged at 100,000g for 1 h to yield the
cytosol. Contamination by lipids was avoided at all
stages of cytosol preparation.
Cytosol (400p1) was incubated, in triplicate, with
[3H]-mibolerone at a single saturating concen-
tration, 10nmoll-1 (Bannister et al., 1985b). Paired
samples were incubated in the presence of a 200-
fold excess of unlabelled mibolerone. A 1000-fold
excess of triamcinolone acetonide was added to all
tubes to block cross reactivity of mibolerone to
progesterone and hydrocortisone receptors (Asselin
et al., 1979; Bannister et al., 1985b). Cytosol
fractions were incubated for 18h, by which time
maximum binding was stable.
Receptors were assayed by the method of Pavlick
and Coulson (1976) as modified by Erdos and
Bessada (1979). Following overnight incubation of
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cytosol fractions 1 ml of hydroxylapatite slurry
(50% v/v) was added to each tube, which was
mixed by vortexing and then on a rotary mixer for
15min. Each sample was filtered onto Whatman
No. 1 filter discs and washed wAth 5 x 5ml TE
buffer. The filter papers were transferred to scintil-
lation vials, 1 ml ethanol added to aid elution of the
steroids, 10ml scintillant ('Optiphase X' Fisons,
Ipswich, Suffolk) added and the vials counted on
a Packard liquid scintillation counter (efficiency
35%). Protein estimation was by the modified biuret
technique (Bradford, 1976). Intra-assay coefficient
of variation for a single saturating dose analysis of
rat liver was 10.1% and interassay coefficient of
variation for rat liver, 12%. The lower detection
limit of the assay was 4fmolmg- I protein.
All data are presented as means+s.e. and the
significances of the differences between two means
was tested by unpaired Student's t-tests.
Histological examination showed that extensive
dysplastic changes occurred in all groups of rats fed
DEN. The degree of dysplasia was correlated with
the time of exposure to DEN; rats fed DEN for 16
weeks had more marked dysplastic changes. Frank
macroscopic tumours occurred in a minority of
animals but these were excluded from analysis.
Androgen receptor levels were significantly higher in
the control rats (n=I1) compared with the nitro-
samine treated (n=11) male rat livers: 17.4+2.17
vs. 6.33 + 1.15 fmolmg- protein; P<0.005 (Figure
la). No correlation was found between the dura-
tion of DEN treatment, the degree of dysplastic
change and the fall in AR concentration. No
difference in protein concentration was noted
between control and DEN treated animals. In the
female rats no significant difference was found
between the control (n = 16) and nitrosamine treated
(n= 13) rats: 5.28+1.98 vs. 6.6+1.15fmolmg-'
protein; P<0.6 (Figure lb). Tissue AR concen-
trations were significantly lower in the female rats
than in the male control groups, P<0.001.
The present study is the first to investigate AR
levels in experimentally induced liver carcinogenesis.
Our findings are in contrast to the data from AR
studies in established human hepatocellular
carcinomas. Iqbal et al. (1983) showed the presence
of raised AR levels in 4 cases of hepatocellular
carcinoma but failed to show binding in normal
liver. Subsequently Nagasue et al. (1985) have
shown raised levels of AR in hepatocellular
carcinoma compared to cirrhotic liver. In the data
from Nagasue et al., cirrhotic liver appears to have
reduced levels of AR compared to normal liver. In
the present experiments we have studied tissue
which is dysplastic but not macroscopically
malignant thus it might be that a reduction in AR
occurs as an integral part of the premalignant
phase of tumour induction, with a subsequent rise
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Figure 1 Androgen receptor levels in control and
nitrosamine-treated (a) male rat livers and (b) female
rat livers.
in tissue AR once the tumour is established. An
alternative explanation is that AR levels are
reduced in a non-specific manner by tissue damage
and then become expressed during the process of
carcinogenesis. This concept is supported by the
fact that liver AR are also reduced in hepatic
steatosis of either congenital (Bannister &
Whitaker, 1985) or alcohol induced aetiology
(Eagon et al., 1985), or in simple chronic active
hepatitis without cirrhosis (Nagasue et al., 1985).
Oestrogen receptor concentrations have also been
reported to be lowered in established experimental
liver tumours. Mishkin et al. (1983) demonstrated
reduced ER levels in rats treated with the
carcinogen acetylaminofluorane. Francavilla et al.
(1984) reported very low levels of cytosolic ER in
the transplanted Morris hepatoma 7777 and in
humans reduced levels of ER have been shown in
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oral contraceptive-associated hepatic adenoma. No
studies have been performed on ER levels during
the pre-malignant phase of tumour production but
in a single case report ER levels were increased in
focal nodular hyperplasia (Porter et al., 1983b).
Thus an increase in ER and a fall in AR may be
important events in hepatic carcinogenesis. The
presence of an androgen receptor in female rat liver
has not been previously reported. AR levels are a
mean of 34% of male AR values. No further
reduction in this value was noted after DEN
treatment. This failure of AR levels to fall after
DEN treatment may reflect lack of sensitivity of the
assay or may be a genuine finding. Does the
finding of AR in liver have clinical implications? In
humans the incidence of hepatocellular carcinomas
is increased in males (Nagasue et al., 1984),
suggesting this may be a hormone-dependent
tumour.
This work was supported by Leeds RHA locally organised
research fund, Grant No. LE 59 and the Yorkshire
Cancer Research Fund.
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